Overview

Clinical Trial of Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

Sintilimab (R&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity. This study is a phase III clinical study of a three-week regimen of sintilimab combined with the XELOX+ bevacizumab for RAS-mutant metastatic colorectal cancer patients who had not received any treatment before. The purpose of this study is to explore the efficacy of sintilimab combined with XELOX + bevacizumab as first line therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Bevacizumab
Capecitabine
Oxaliplatin